- Home
- SPT vs AUTL Comparison
SPT vs AUTL Comparison
Compare SPT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPT | AUTL |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.6M | 388.6M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SPT | AUTL |
|---|---|---|
| Price | $6.63 | $1.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $11.75 | $8.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $457,547,000.00 | $10,120,000.00 |
| Revenue This Year | $8.86 | $80.32 |
| Revenue Next Year | $8.04 | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.72 | ★ 496.00 |
| 52 Week Low | $4.92 | $1.18 |
| 52 Week High | $21.53 | $2.70 |
Technical Indicators
Market Signals| Indicator | SPT | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 45.03 |
| Support Level | $5.94 | $1.41 |
| Resistance Level | $7.45 | $1.52 |
| Average True Range (ATR) | 0.47 | 0.12 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 1.12 | 25.60 |
Price Performance
Historical ComparisonAbout SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.